OvaScience, the innovative fertility treatment company, received an acquisition offer from PG Ventures, a private equity firm, in April 20123. OvaScience has developed its first fertility treatment, AUGMENT (Autologous Germ-line Mitochondrial Energy Transfer) as this treatment could enhance egg quality, increase the success of IVF cycles, and decrease the rate of multiple births at a time like twins, triplets. The company was founded in 2011 and AUGMENT was not launched by the company yet. Michelle Dipp, the CEO and co-founder of OvaScience, and her partners expected the dramatic success of AUGMENT and the outcomes based on this technology could have one million cases across the world. What could be the highest growth rate that the Dipp and her team could bring to OvaScience? Would they have the assets? The CEO considered the most ideal approach to develop OvaScience’s business model and whether AUGMENT’s potential exceeded the PG offer.
Related Case Solutions & Analyses:
Agnellis and the Fiat Group: The Story of a Family Empire (A)
Haiers U.S. Refrigerator Strategy 2005
From Silicon Island to Biopolis of Asia: Innovation Policy and Shifting Competitive Strategy in Singapore
Rise and Decline of Labor-Management Cooperation: Lessons from Health Care in the Twin Cities
Kronos (A)
BRITISH AIRPORTS AUTHORITY: PART (A)
Strategic Capital Management
Adam Baxter Co./Local 190: 1985 Negotiation, Local 190 Confidential Information
Colliers International Property Consultants, Inc.: Managing a Virtual Organization
3M: Negotiating Air Pollution Credits (C)
